Disclosure Statement

Joint Working Project between;
- Northern Centre for Cancer Care (NCCC) at Newcastle upon Tyne Hospitals NHS Trust ("NuTH") and Bristol-Myers Squibb Pharmaceuticals Limited ("BMS")

<table>
<thead>
<tr>
<th>Name of Project</th>
<th>Reducing Time to Treatment Administration (RTTA) Phase 2 – Moving from identifying the problem to improving treatment efficiencies (the “Project”)</th>
</tr>
</thead>
</table>
| Project Overview | The project will  
- Quantify, analyse and baseline the current pathway of patients attending the Tuesday Melanoma clinic at the Newcastle Centre for Cancer Care from the patient arriving to receiving their treatment  
- Redesign the future pathway, identifying required service elements for change to address patient waiting times  
- Evaluate immediate change within the pathway as it happens and prepare longer term service proposals for the trust to implement as appropriate following the completion of this project  
As a result of understanding the baseline, one or two small tests of change will be piloted within the scope of the project to test the impact on the pathway as agreed by the project board. On completion of the project there will a planned six-month evaluation with insights and outcomes shared across both parties. In addition, a list of longer-term proposals may be agreed – implementation of these longer-term proposals will be out of scope of this project. |
| Project Objectives | Aim;  
- To build on current changes (from Phase 1) to the current patient pathway within the Tuesday Melanoma Clinics by introducing treatment efficiencies to reduce time spent in department by 50% and time spent by established patients waiting to start treatment. This should then in turn improve patient satisfaction with the service.  
Objectives;  
1. To capture patient experience for patients already on treatment  
   - Those attending from home  
   - Those attending clinic first  
2. To quantify waiting times for each stage in the pathway  
   - Clinic – Chemo Reception – Bloods – Treatment – Home  
3. To create model of route taken by patients to receive treatment  
   - Use this to identify problems/solutions to improve efficiency at each stage  
4. To immediately implement short term solutions whilst highlighting possible longer-term solutions for future implementation  
5. To test out the above solutions by re-capturing the patient’s perspective |
| Patient Benefits | 1. Improved satisfaction in service provided by patients attending the Tuesday Melanoma Clinic  
2. Reduction in waiting times on day of treatment  
3. Shorter waiting time to start treatment – resulting in reduced anxiety |
| Stakeholders | Newcastle upon Tyne Hospitals NHS Foundation Trust (“NuTH”)  
Bristol-Myers Squibb (BMS) |
| Timelines | The Project will start from the date on which the disclosure statement goes live on the BMS Pharmaceuticals Ltd website and will finish 12 months after this date. |

Produced by Bristol-Myers Squibb Pharmaceuticals Ltd with Newcastle upon Tyne Hospitals Foundation NHS Trust ("NuTH")